Verve Therapeutics Inc. (VERV) - Forward P/S Multiple

Verve Therapeutics (VERV) is tapping into a colossal market for hypercholesterolemia treatment by implementing advanced CRISPR technologies for one-time genome correction. The forward P/S ratio reflects volatile revenue expectations, where 16.60 indicates the current level of market equilibrium. This valuation trend is coupled with strategic partnerships with pharmaceutical behemoths, which are accelerating the commercialization of innovative cardiology drugs.

VERV Verve Therapeutics, Inc.: Forward Price to Sales in the range 11/14/2022 - 08/09/2025

Financial and market metric breakdowns for Verve Therapeutics, Inc. (VERV)

- current price and projected stock value:

Stock Price Verve Therapeutics|VERV - Fair Value Consensus

- market capitalization indicators:

Market Capitalization Verve Therapeutics, Inc.|VERV - Total Enterprise Value

- issuer book value statistics:

Net Assets per Single Share Verve Therapeutics|VERV - Accounting Value of Company|Market Capitalization to Book Value Ratio vervetx.com|VERV - Company Total Assets

- debt and liquidity data:

- business earnings and investment ratios data:

VERV - Net Financial Result|Projected Future Earnings Verve Therapeutics|VERV - Price to Earnings Ratio|Future Price to Earnings vervetx.com|VERV - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio Verve Therapeutics, Inc.|VERV - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Verve Therapeutics|VERV - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months vervetx.com|VERV - Earnings per share increase in current year|Expected earnings per share growth for next year Verve Therapeutics

- company sales and revenue statistics:

VERV - Company Revenue|Projected Sales Volume Verve Therapeutics|VERV - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Verve Therapeutics, Inc.|VERV - Trailing Twelve Months Revenue Growth

Initial company analysis:Verve Therapeutics (VERV)

Forward P/S determines the market value of an asset relative to its projected revenue, allowing for an assessment of whether a company is overvalued or undervalued in the event of a potential acquisition. Analyzing the expected P/S metric compares market capitalization with future cash flows, which is critical for Verve Therapeutics (VERV) given the high maintenance costs of gene-editing laboratories and automated screening systems for cardiac pathologies.

Competitors of Verve Therapeutics

Price-to-Projected Revenue Ratio regeneron.com REGN|Forward Price to Sales IRTC|LNTH: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Mineralys Therapeutics, Inc. MLYS|HTFL (HeartFlow) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue KMTS|ESPR (Esperion Therapeutics Inc) - Forward P/S Multiple|Amarin Pharma - Future Price to Revenue|Price-to-Projected Revenue Ratio Anteris Technologies Ltd (AVR)|Forward P/S Multiple Tenaya (TNYA)|CVRx, Inc - Forward Price-to-Revenue Multiple|Forward P/S Multiple Milestone Pharmaceuticals, Inc. MIST|CRDL - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio HeartBeam Corp BEAT|TENX (Tenax Therapeutics, Inc) - Forward Price-to-Revenue Multiple|Adagio Medical Holdings - Forward Price to Sales|BCDA (BioCardia Inc.) - Forward P/S Multiple|Catheter Precision Inc (VTAK) - Market Cap to Expected Sales Ratio|Forward P/S Multiple ABIO|Price to Expected Revenue Ratio ACST|Aerovate - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio WINT (Windtree)